TITLE

Effects of Guanfacine Extended Release on Oppositional Symptoms in Children Aged 6-12 Years with Attention-Deficit Hyperactivity Disorder and Oppositional Symptoms

AUTHOR(S)
Connor, Daniel F.; Findling, Robert L.; Kollins, Scott H.; Sallee, Floyd; Lopez, Frank A.; Lyne, Andrew; Tremblay, Gerald
PUB. DATE
September 2010
SOURCE
CNS Drugs;2010, Vol. 24 Issue 9, p755
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To evaluate the efficacy and safety of guanfacine extended release (XR, Intunivâ„¢; Shire Development Inc., Wayne, PA, USA) in the treatment of oppositional symptoms in children aged 6-12 years with a diagnosis of attention-deficit hyperactivity disorder (ADHD) and the presence of oppositional symptoms. Subjects and Methods: In this randomized, double-blind, placebo-controlled, multicentre, flexible-dose, dose-optimization study, children aged 6-12 years were randomized to receive guanfacine XR (1-4 mg/day) or placebo for 9 weeks. Screening and washout periods were followed by a 5-week dose-optimization period, a 3-week dose-maintenance period and a 1-week tapering period. The primary efficacy measure was change from baseline to endpoint in the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) score. Change in ADHD Rating Scale IV (ADHD-RS-IV) total score was a secondary efficacy measure. Safety assessments included adverse events (AEs), vital signs, ECG readings and laboratory studies. Results: A total of217 children were enrolled: 138 were randomized to receive guanfacine XR and 79 to receive placebo. Least-squares mean reductions from baseline to endpoint in CPRS-R:L oppositional subscale scores were 10.9 in the guanfacine XR group compared with 6.8 in the placebo group (p<0.00l; effect size=0.59). A significantly greater reduction in ADHDRS-IV total score from baseline to endpoint was also seen in the.guanfacinetreated group compared with the placebo group (23.8 vs 11.5, respectively; p
ACCESSION #
55455285

 

Related Articles

  • Finding Guidance Amid Uncertainty of ADHD Diagnosis. Shakil, Amer // American Family Physician;5/1/2001, Vol. 63 Issue 9, p1694 

    Editorial. Focuses on issues related to the management of attention-deficit hyperactivity disorder (ADHD) among children. Establishment of criteria for ADHD; Recommendations for the management of ADHD; Importance of screening the school performance of children.

  • Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial [ISRCTN64132371]. Akhondzadeh, Shahin; Mohammadi, Mohammad-Reza; Khademi, Mojgan // BMC Psychiatry;2004, Vol. 4, p9 

    Background: Attention-deficit hyperactivity disorder is an early-onset, clinically heterogenous disorder of inattention, hyperactivity, and impulsiveness. The diagnosis and treatment of attention-deficit hyperactivity disorder continues to raise controversy, and, there is also an increase in...

  • FDA Preliminary Report: Safety of Stimulant Medications. Stein, Martin T. // Archives of Disease in Childhood;Jul2006, Vol. 91 Issue 7, p619 

    The article reports that a U.S. Food and Drug Administration committee has voted to recommend that stimulant medications prescribed for attention deficit hyperactivity disorder (ADHD) carry a strong "black box" warning about potential cardiovascular risks. Pediatricians who prescribe medications...

  • Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. Sonuga-Barke, Edmund J. S.; Swanson, James M.; Coghill, David; DeCory, Heleen H.; Hatch, Simon J. // BMC Psychiatry;2004, Vol. 4, p28 

    Background: Methylphenidate (MPH) is commonly prescribed in the treatment of Attention-Deficit/ Hyperactivity Disorder or ADHD. Concerta and Metadate CD are once-daily formulations of MPH using different delivery mechanisms resulting in different pharmacokinetic profiles. A recent study (COMACS)...

  • When preschool children have ADHD.  // Archives of Disease in Childhood;May2007, Vol. 92 Issue 5, p464 

    The article comments on the results of the Preschool ADHD Treatment Study, a randomized trial of the efficacy and safety of methylphenidate (MPH) in preschool children. According to the author, the results of the study demonstrate the effectiveness of stimulant medication in the treatment of...

  • Letters.  // CMAJ: Canadian Medical Association Journal;5/14/2002, Vol. 166 Issue 10, p1251 

    Presents letters to the editor regarding medical issues. Need for physicians to have access to randomized controlled trials that evaluate new drugs; Alleged bias in the work of Rebecca Pollex and colleagues on celestial determinants of success in research; Treatment of attention-deficit...

  • THE IMPACT OF CULTURE ON ADHD. Starr, H. Lynn // Contemporary Pediatrics;Dec2007, Vol. 24 Issue 12, p38 

    The article analyzes the effect of ethnicity on the diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD). According to the author, the cultural background of the patient with ADHD and his or her parents can cause unsettled reaction to pharmacological interventions of the...

  • Suicidality risk associated with atomoxetine.  // WHO Drug Information;2006, Vol. 20 Issue 1, p9 

    The article reports on the approval of a norepinephrine re-uptake inhibitor atomoxetine, for the treatment of attention deficit hyperactivity disorder in children 6 years of age and older, in adolescents and adults. According to the manufacturer of the drug, there is an increased risk of...

  • Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Mészáros, Ágnes; Czobor, Pál; Bálint, Sára; Komlósi, Sarolta; Simon, Viktória; Bitter, István // International Journal of Neuropsychopharmacology;Sep2009, Vol. 12 Issue 8, p1137 

    Our objective was to conduct a meta-analysis of therapeutic efficacy of pharmacological treatment of adult ADHD based on data from controlled clinical trials. We used the search engines PubMed and Medline to identify relevant clinical trials. Short-term studies with double-blind parallel-group...

  • Does diet affect ADHD? Logan, Alan C. // Alive: Canada's Natural Health & Wellness Magazine;Sep2008, Issue 311, p87 

    The article reports on the crucial role of diet in preventing the causation of attention-deficit hyperactivity disorder (ADHD) in children. It is evident that the food children eat can influence the structure and function of neurons and the brain requires steady stream of nutrients to function...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics